Popular Trials
Checkpoint Inhibitor
Nivolumab After Bone Marrow Transplant for Sarcoma
Recruiting1 awardPhase 1 & 2
Saint Petersburg, Florida
This trial is testing if the investigational drug Nivolumab is safe to take after a "half-matched" bone marrow transplant, and if it helps prevent or delay relapse or progression of sarcomas.
Popular Filters
Trials for Soft Tissue Sarcoma Patients
Kinase Inhibitor
Turalio for Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
Recruiting2 awardsPhase 3
San Francisco, California
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
Trials for Rhabdomyosarcoma Patients
Kinase Inhibitor
Turalio for Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
Recruiting2 awardsPhase 3
San Francisco, California
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
Trials for Metastatic Patients
CDK4/6 Inhibitor
Abemaciclib for Liposarcoma
Recruiting3 awardsPhase 2
New York, New York
This trial is testing the effects of the drug Abemaciclib on cancer growth. Researchers hope to learn if the drug can delay cancer growth or shrink tumors. Abemaciclib is not FDA approved, but has shown promise in shrinking tumors in patients with breast cancer, lymphoma, and lung cancer.
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
Recruiting2 awardsPhase 3
San Francisco, California
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
CAR T-cell Therapy
CAR T-Cell Therapy for Sarcoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new cancer treatment that uses patients' own immune cells. Researchers will insert a new gene into the cells that will make them better at fighting the cancer. The cells will be given to patients after they have received chemotherapy, which should help the cells to better fight the cancer.
Trials With No Placebo
CDK4/6 Inhibitor
Abemaciclib for Liposarcoma
Recruiting3 awardsPhase 2
New York, New York
This trial is testing the effects of the drug Abemaciclib on cancer growth. Researchers hope to learn if the drug can delay cancer growth or shrink tumors. Abemaciclib is not FDA approved, but has shown promise in shrinking tumors in patients with breast cancer, lymphoma, and lung cancer.
Kinase Inhibitor
Turalio for Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.